JP2016501843A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501843A5
JP2016501843A5 JP2015540216A JP2015540216A JP2016501843A5 JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5 JP 2015540216 A JP2015540216 A JP 2015540216A JP 2015540216 A JP2015540216 A JP 2015540216A JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
lymphoma
fragments
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015540216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501843A (ja
Filing date
Publication date
Priority claimed from GBGB1220010.1A external-priority patent/GB201220010D0/en
Application filed filed Critical
Publication of JP2016501843A publication Critical patent/JP2016501843A/ja
Publication of JP2016501843A5 publication Critical patent/JP2016501843A5/ja
Pending legal-status Critical Current

Links

JP2015540216A 2012-11-07 2013-11-06 癌治療および判断ターゲットとしてのly75 Pending JP2016501843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1220010.1 2012-11-07
GBGB1220010.1A GB201220010D0 (en) 2012-11-07 2012-11-07 Therapeutic amd diagnostic target
PCT/GB2013/052899 WO2014072700A1 (en) 2012-11-07 2013-11-06 Ly75 as cancer therapeutic and diagnostic target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018141190A Division JP7079685B2 (ja) 2012-11-07 2018-07-27 癌治療および判断ターゲットとしてのly75

Publications (2)

Publication Number Publication Date
JP2016501843A JP2016501843A (ja) 2016-01-21
JP2016501843A5 true JP2016501843A5 (enExample) 2016-11-24

Family

ID=47429281

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015540216A Pending JP2016501843A (ja) 2012-11-07 2013-11-06 癌治療および判断ターゲットとしてのly75
JP2018141190A Active JP7079685B2 (ja) 2012-11-07 2018-07-27 癌治療および判断ターゲットとしてのly75
JP2020154083A Pending JP2021011483A (ja) 2012-11-07 2020-09-14 癌治療および判断ターゲットとしてのly75
JP2022177986A Active JP7479435B2 (ja) 2012-11-07 2022-11-07 癌治療および判断ターゲットとしてのly75

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018141190A Active JP7079685B2 (ja) 2012-11-07 2018-07-27 癌治療および判断ターゲットとしてのly75
JP2020154083A Pending JP2021011483A (ja) 2012-11-07 2020-09-14 癌治療および判断ターゲットとしてのly75
JP2022177986A Active JP7479435B2 (ja) 2012-11-07 2022-11-07 癌治療および判断ターゲットとしてのly75

Country Status (15)

Country Link
US (3) US20150297743A1 (enExample)
EP (1) EP2917239A1 (enExample)
JP (4) JP2016501843A (enExample)
KR (1) KR102256552B1 (enExample)
CN (2) CN113181372A (enExample)
AU (2) AU2013343277B2 (enExample)
BR (1) BR112015009438B1 (enExample)
CL (1) CL2015001098A1 (enExample)
EA (1) EA033649B1 (enExample)
GB (1) GB201220010D0 (enExample)
HK (1) HK1214611A1 (enExample)
NZ (1) NZ707116A (enExample)
SG (2) SG10201810357WA (enExample)
UA (1) UA117569C2 (enExample)
WO (1) WO2014072700A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220010D0 (en) * 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
CN105745224B (zh) 2013-10-11 2019-11-05 牛津生物疗法有限公司 用于治疗癌症的针对ly75的偶联抗体
AU2016269632B2 (en) 2015-05-29 2021-09-09 Mla Diagnostics B.V. Method for identifying subjects with aggressive melanoma skin cancer at diagnosis
KR101796091B1 (ko) 2016-05-02 2017-11-10 충남대학교 산학협력단 카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN109685135B (zh) * 2018-12-21 2022-03-25 电子科技大学 一种基于改进型度量学习的少样本图像分类方法
JP7797384B2 (ja) * 2019-11-26 2026-01-13 シーダーズ-サイナイ メディカル センター 循環からミトコンドリアdna又はゲノムdnaを枯渇させることにより疾患及び症状を治療する組成物及び方法
WO2023032994A1 (ja) 2021-08-31 2023-03-09 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
WO2023032996A1 (ja) 2021-08-31 2023-03-09 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
JPWO2023032995A1 (enExample) 2021-08-31 2023-03-09
JP2024533459A (ja) * 2021-09-13 2024-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド リンパ球抗原75(ly75)、表面抗原分類164(cd164)、またはポリ(adp-リボース)ポリメラーゼ1(parp1)阻害剤を用いた未確定の潜在能をもつクローン性造血(chip)の治療方法
JPWO2024143263A1 (enExample) 2022-12-26 2024-07-04
CN120752249A (zh) 2023-02-27 2025-10-03 富士胶片株式会社 化合物及使用了该化合物的标记生物物质
WO2024181454A1 (ja) 2023-02-27 2024-09-06 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
KR20260023583A (ko) 2023-08-31 2026-02-20 후지필름 가부시키가이샤 표적화 약물 복합체 및 이것을 포함하는 의약, 및, 화합물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
JP2000512490A (ja) * 1996-05-29 2000-09-26 デレク ナイジェル ジョン ハート 樹状細胞のレセプター
KR20080087184A (ko) * 2001-01-31 2008-09-30 바이오겐 아이덱 인크. 종양질환 치료를 위한 cd23 길항제의 용도
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
CN101888856B (zh) * 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
EP2159291A1 (en) * 2008-09-01 2010-03-03 Agendia B.V. Means and method for determining tumor cell percentage in a sample
AU2010303304A1 (en) * 2009-10-08 2012-05-17 President And Fellows Of Harvard College Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
GB201220010D0 (en) * 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
JP6431104B2 (ja) * 2017-02-27 2018-11-28 オリコン株式会社 マイクロ波を利用した金属蒸気の発生方法

Similar Documents

Publication Publication Date Title
JP2016501843A5 (enExample)
Dogan et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target
RU2017132214A (ru) Анти-pvrig антитела и способы применения
CY1124634T1 (el) Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
JP2010518847A5 (enExample)
Hayes et al. Antitumor activity of an anti‐CD 98 antibody
JP2011509079A5 (enExample)
JP2016500110A5 (enExample)
EA201691144A1 (ru) Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка
JP2019504321A5 (enExample)
JP2017518366A5 (enExample)
JP2014530877A5 (enExample)
JP2008538289A5 (enExample)
JP2009536834A5 (enExample)
JP2013507968A5 (enExample)
RU2014140119A (ru) Способы повышения эффективности терапии на основе cd37
JP2015514716A5 (enExample)
WO2015192081A1 (en) Biomarker for predicting response of cll to treatment with a btk inhibitor
Afonso et al. QCM immunoassay for recombinant cysteine peptidase: A potential protein biomarker for diagnosis of citrus canker
JP2010535506A5 (enExample)
JP2015523852A5 (enExample)
JP2014223083A5 (enExample)
JP2018532699A5 (enExample)